Journal ArticleDOI
Therapeutic options for the 2019 novel coronavirus (2019-nCoV).
Guangdi Li,Erik De Clercq +1 more
TLDR
The potential for repurposing existing antiviral agents to treat 2019-nCoV infection (now known as COVID-19) is discussed, some of which are already moving into clinical trials.Citations
More filters
Journal ArticleDOI
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.
TL;DR: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918 and both the need and capability to produce high-quality evidence even in the middle of a pandemic.
Journal ArticleDOI
Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target.
Haibo Zhang,Haibo Zhang,Haibo Zhang,Josef M. Penninger,Josef M. Penninger,Yimin Li,Nanshan Zhong,Arthur S. Slutsky,Arthur S. Slutsky,Arthur S. Slutsky +9 more
TL;DR: The rationale for angiotensin-converting enzyme 2 (ACE2) receptor as a specific target is reviewed, and a number of pharmaceuticals already being tested are tested but a better understanding of the underlying pathobiology is required.
Journal ArticleDOI
SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues.
Carly G. K. Ziegler,Samuel J. Allon,Sarah K. Nyquist,Ian M. Mbano,Vincent N. Miao,Constantine N. Tzouanas,Yuming Cao,Ashraf S. Yousif,Julia Bals,Blake M. Hauser,Blake M. Hauser,Jared Feldman,Jared Feldman,Christoph Muus,Christoph Muus,Marc H. Wadsworth,Samuel W. Kazer,Travis K. Hughes,Benjamin Doran,G. James Gatter,G. James Gatter,G. James Gatter,Marko Vukovic,Faith Taliaferro,Faith Taliaferro,Benjamin E. Mead,Zhiru Guo,Jennifer P. Wang,Delphine Gras,Magali Plaisant,Meshal Ansari,Ilias Angelidis,Heiko Adler,Jennifer M.S. Sucre,Chase J. Taylor,Brian M. Lin,Avinash Waghray,Vanessa Mitsialis,Vanessa Mitsialis,Daniel F. Dwyer,Kathleen M. Buchheit,Joshua A. Boyce,Nora A. Barrett,Tanya M. Laidlaw,Shaina L. Carroll,Lucrezia Colonna,Victor Tkachev,Victor Tkachev,Christopher W. Peterson,Christopher W. Peterson,Alison Yu,Alison Yu,Hengqi Betty Zheng,Hengqi Betty Zheng,Hannah P. Gideon,Caylin G. Winchell,Philana Ling Lin,Philana Ling Lin,Colin D. Bingle,Scott B. Snapper,Scott B. Snapper,Jonathan A. Kropski,Jonathan A. Kropski,Fabian J. Theis,Herbert B. Schiller,Laure-Emmanuelle Zaragosi,Pascal Barbry,Alasdair Leslie,Alasdair Leslie,Hans-Peter Kiem,Hans-Peter Kiem,JoAnne L. Flynn,Sarah M. Fortune,Sarah M. Fortune,Sarah M. Fortune,Bonnie Berger,Robert W. Finberg,Leslie S. Kean,Leslie S. Kean,Manuel Garber,Aaron G. Schmidt,Aaron G. Schmidt,Daniel Lingwood,Alex K. Shalek,Jose Ordovas-Montanes,Nicholas E. Banovich,Alvis Brazma,Tushar J. Desai,Thu Elizabeth Duong,Oliver Eickelberg,Christine S. Falk,Michael Farzan,Ian A. Glass,Muzlifah Haniffa,Peter Horvath,Deborah T. Hung,Naftali Kaminski,Mark A. Krasnow,Malte Kühnemund,Robert Lafyatis,Haeock Lee,Sylvie Leroy,Sten Linnarson,Joakim Lundeberg,Kerstin B. Meyer,Alexander V. Misharin,Martijn C. Nawijn,Marko Nikolic,Dana Pe'er,Joseph E. Powell,Stephen R. Quake,Jay Rajagopal,Purushothama Rao Tata,Emma L. Rawlins,Aviv Regev,Paul A. Reyfman,Mauricio Rojas,Orit Rosen,Kourosh Saeb-Parsy,Christos Samakovlis,Herbert B. Schiller,Joachim L. Schultze,Max A. Seibold,Douglas P. Shepherd,Jason R. Spence,Avrum Spira,Xin Sun,Sarah A. Teichmann,Fabian J. Theis,Alexander M. Tsankov,Maarten van den Berge,Michael von Papen,Jeffrey A. Whitsett,Ramnik J. Xavier,Yan Xu,Kun Zhang +135 more
TL;DR: The data suggest that SARS-CoV-2 could exploit species-specific interferon-driven upregulation of ACE2, a tissue-protective mediator during lung injury, to enhance infection.
Journal ArticleDOI
The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
TL;DR: Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection able to effect ~5000-fold reduction in viral RNA at 48 h.
Journal ArticleDOI
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Ivan Hung,Kwok Cheung Lung,Eugene Yuk Keung Tso,Raymond W. Liu,Tom Wai-Hin Chung,Man Yee Chu,Yuk Yung Ng,Jenny Lo,Jacky Chan,Anthony Raymond Tam,Hoi-Ping Shum,Veronica L. Chan,Alan Ka Lun Wu,Kit Man Sin,Wai Shing Leung,Wai Lam Law,David Christopher Lung,Simon Yung Wa Sin,Pauline Yeung,Cyril C. Y. Yip,Ricky Ruiqi Zhang,Agnes Yim Fong Fung,Erica Yuen Wing Yan,Kit-Hang Leung,Jonathan Daniel Ip,Allen Wing-Ho Chu,Wan Mui Chan,Anthony Chin-Ki Ng,Rodney A. Lee,Kitty S. C. Fung,Alwin Wt Yeung,Tak Chiu Wu,Johnny W.M. Chan,Wing Wah Yan,Wai-Ming Chan,Jasper Fuk-Woo Chan,Albert K. W. Lie,Owen Tak Yin Tsang,Vincent C.C. Cheng,Tak-Lun Que,Chak Sing Lau,Kwok-Hung Chan,Kelvin K. W. To,Kwok-Yung Yuen +43 more
TL;DR: Yu et al. as mentioned in this paper assessed the efficacy and safety of combined interferon beta-1b, lopinavir-ritonavir, and ribavirin for treating patients with COVID-19.
References
More filters
Journal ArticleDOI
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.
Manli Wang,Ruiyuan Cao,Leike Zhang,Xing-Lou Yang,Jia Liu,Mingyue Xu,Zhengli Shi,Zhihong Hu,Wu Zhong,Gengfu Xiao +9 more
TL;DR: This study evaluated the antiviral efficiency of five FAD-approved drugs including ribavirin, penciclovir, nitazoxanide, nafamostat, chloroquine and two well-known broad-spectrum antiviral drugs remdesivir and favipiravir against a clinical isolate of 2019-nCoV in vitro.
Journal ArticleDOI
First Case of 2019 Novel Coronavirus in the United States.
Michelle Holshue,Chas DeBolt,Scott Lindquist,Kathy H Lofy,John Wiesman,Hollianne Bruce,Christopher Spitters,Keith M. Marzilli Ericson,Sara Wilkerson,Ahmet Tural,George Diaz,Amanda C. Cohn,LeAnne Fox,Anita Patel,Susan I. Gerber,Lindsay Kim,Suxiang Tong,Xiaoyan Lu,Steve Lindstrom,Mark A. Pallansch,William C. Weldon,Holly M. Biggs,Timothy M. Uyeki,Satish K. Pillai +23 more
TL;DR: This case highlights the importance of close coordination between clinicians and public health authorities at the local, state, and federal levels, as well as the need for rapid dissemination of clinical information related to the care of patients with this emerging infection.
Journal ArticleDOI
Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV.
Timothy P. Sheahan,Amy C. Sims,Sarah R. Leist,Alexandra Schäfer,John J. Won,Ariane J. Brown,Stephanie A. Montgomery,Alison Hogg,Darius Babusis,Michael O'neil Hanrahan Clarke,Jamie E. Spahn,Bauer Laura Elizabeth,Scott P. Sellers,Danielle P. Porter,Joy Y. Feng,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +18 more
TL;DR: Remdesivir (RDV) has superior anti-MERS activity in vitro and in vivo compared to combination therapy with lopinavir, ritonavir and interferon beta and reduces severe lung pathology.
Journal ArticleDOI
Coronaviruses - drug discovery and therapeutic options.
TL;DR: The epidemiology, virology, clinical features and current treatment strategies of SARS and MERS are summarized, and the discovery and development of new virus-based and host-based therapeutic options for CoV infections are discussed.
Journal ArticleDOI
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Timothy P. Sheahan,Amy C. Sims,Rachel L. Graham,Vineet D. Menachery,Lisa E. Gralinski,James Brett Case,Sarah R. Leist,Krzysztof Pyrc,Joy Y. Feng,Iva Trantcheva,Roy Bannister,Yeojin Park,Darius Babusis,Michael O. Clarke,Richard L. Mackman,Jamie E. Spahn,Christopher A. Palmiotti,Dustin Siegel,Adrian S. Ray,Tomas Cihlar,Robert Jordan,Mark R. Denison,Ralph S. Baric +22 more
TL;DR: Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses in vitro and in vivo and may prove effective against endemic MERS-CoV in the Middle East, circulating human CoV, and, possibly most importantly, emerging CoV of the future.
Related Papers (5)
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
Chaolin Huang,Yeming Wang,Xingwang Li,Lili Ren,Jianping Zhao,Yi Hu,Li Zhang,Guohui Fan,Jiuyang Xu,Xiaoying Gu,Zhenshun Cheng,Ting Yu,Jia'an Xia,Yuan Wei,Wenjuan Wu,Xuelei Xie,Wen Yin,Li Hui,Min Liu,Yan Xiao,Hong Gao,Li Guo,Jungang Xie,Guang-Fa Wang,Rongmeng Jiang,Zhancheng Gao,Qi Jin,Jianwei Wang,Bin Cao +28 more
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Peng Zhou,Xing-Lou Yang,Xian Guang Wang,Ben Hu,Lei Zhang,Wei Zhang,Hao Rui Si,Yan Zhu,Bei Li,Chao Lin Huang,Hui-Dong Chen,Jing Chen,Yun Luo,Hua Guo,Ren Di Jiang,Meiqin Liu,Ying Chen,Xu Rui Shen,Xi Wang,Xiao Shuang Zheng,Kai Zhao,Quanjiao Chen,Fei Deng,Lin Lin Liu,Bing Yan,Fa Xian Zhan,Yan-Yi Wang,Gengfu Xiao,Zhengli Shi +28 more